Last updated on June 2019

A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome


Brief description of study

An Open Label, Intra-Subject Dose Escalation Study of CCX140 B in Subjects with Primary FSGS and Nephrotic Syndrome

Detailed Study Description

An Open Label, Intra-Subject Dose Escalation Study of CCX140 B in Subjects with Primary Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic Syndrome. The aim of this study is to explore the effect of CCX140-B, a selective antagonist of C-C chemokine receptor type 2, on proteinuria in subjects with FSGS.

Clinical Study Identifier: NCT03703908

Find a site near you

Start Over

Utah Kidney Research Institute

Salt Lake City, UT United States
5.87miles
  Connect »